CRUK Scotland Institute, Glasgow, United Kingdom.
School of Cancer Sciences, MVLS, University of Glasgow, Glasgow, United Kingdom.
Cancer Res Commun. 2024 Feb 29;4(2):588-606. doi: 10.1158/2767-9764.CRC-23-0319.
Neutrophils are a highly heterogeneous cellular population. However, a thorough examination of the different transcriptional neutrophil states between health and malignancy has not been performed. We utilized single-cell RNA sequencing of human and murine datasets, both publicly available and independently generated, to identify neutrophil transcriptomic subtypes and developmental lineages in health and malignancy. Datasets of lung, breast, and colorectal cancer were integrated to establish and validate neutrophil gene signatures. Pseudotime analysis was used to identify genes driving neutrophil development from health to cancer. Finally, ligand-receptor interactions and signaling pathways between neutrophils and other immune cell populations in primary colorectal cancer and metastatic colorectal cancer were investigated. We define two main neutrophil subtypes in primary tumors: an activated subtype sharing the transcriptomic signatures of healthy neutrophils; and a tumor-specific subtype. This signature is conserved in murine and human cancer, across different tumor types. In colorectal cancer metastases, neutrophils are more heterogeneous, exhibiting additional transcriptomic subtypes. Pseudotime analysis implicates IL1β/CXCL8/CXCR2 axis in the progression of neutrophils from health to cancer and metastasis, with effects on T-cell effector function. Functional analysis of neutrophil-tumoroid cocultures and T-cell proliferation assays using orthotopic metastatic mouse models lacking Cxcr2 in neutrophils support our transcriptional analysis. We propose that the emergence of metastatic-specific neutrophil subtypes is driven by the IL1β/CXCL8/CXCR2 axis, with the evolution of different transcriptomic signals that impair T-cell function at the metastatic site. Thus, a better understanding of neutrophil transcriptomic programming could optimize immunotherapeutic interventions into early and late interventions, targeting different neutrophil states.
We identify two recurring neutrophil populations and demonstrate their staged evolution from health to malignancy through the IL1β/CXCL8/CXCR2 axis, allowing for immunotherapeutic neutrophil-targeting approaches to counteract immunosuppressive subtypes that emerge in metastasis.
中性粒细胞是一种高度异质的细胞群体。然而,人们尚未对健康状态和恶性肿瘤之间不同的中性粒细胞转录状态进行全面研究。我们利用人类和鼠类公开和独立生成的单细胞 RNA 测序数据集,鉴定健康和恶性肿瘤中性粒细胞的转录组亚型和发育谱系。整合肺癌、乳腺癌和结直肠癌数据集,建立和验证中性粒细胞基因特征。采用拟时间分析确定从健康到癌症驱动中性粒细胞发育的基因。最后,研究了原发性结直肠癌和转移性结直肠癌中中性粒细胞与其他免疫细胞群体之间的配体-受体相互作用和信号通路。我们在原发性肿瘤中定义了两种主要的中性粒细胞亚型:一种激活的亚型具有健康中性粒细胞的转录组特征;另一种是肿瘤特异性亚型。该特征在鼠类和人类癌症中是保守的,跨越不同的肿瘤类型。在结直肠癌转移中,中性粒细胞更加异质,表现出更多的转录组亚型。拟时间分析表明,IL1β/CXCL8/CXCR2 轴在中性粒细胞从健康到癌症和转移的进展中起作用,并影响 T 细胞效应功能。使用缺乏中性粒细胞 Cxcr2 的原位转移性小鼠模型进行中性粒细胞-肿瘤样细胞共培养和 T 细胞增殖测定的功能分析支持我们的转录分析。我们提出,转移性特异性中性粒细胞亚型的出现是由 IL1β/CXCL8/CXCR2 轴驱动的,具有不同的转录信号,在转移部位损害 T 细胞功能。因此,更好地了解中性粒细胞转录编程可以优化免疫治疗干预,包括早期和晚期干预,靶向不同的中性粒细胞状态。
我们鉴定了两种重现的中性粒细胞群体,并通过 IL1β/CXCL8/CXCR2 轴展示了它们从健康到恶性肿瘤的分阶段进化,这使得针对免疫抑制性亚型的免疫治疗中性粒细胞靶向方法成为可能,这些亚型在转移中出现。